Target potential of miRNAs in ulcerative colitis: what do we know?

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-09-25 DOI:10.1080/14728222.2024.2408423

Peeyush Kumar, Saurabh Kedia, Vineet Ahuja

{"title":"Target potential of miRNAs in ulcerative colitis: what do we know?","authors":"Peeyush Kumar, Saurabh Kedia, Vineet Ahuja","doi":"10.1080/14728222.2024.2408423","DOIUrl":null,"url":null,"abstract":"Introduction: The global rise in ulcerative colitis (UC) incidence highlights the urgent need for enhanced diagnostic and therapeutic strategies. Recent advances in genome-wide association studies (GWAS) have identified genetic loci associated with UC, providing insights into the disease's molecular mechanisms, including immune modulation, mucosal defense, and epithelial barrier function. Despite these findings, many GWAS signals are located in non-coding regions and are linked to low risk, suggesting that protein-coding genes alone do not fully explain UC's pathophysiology. Emerging research emphasizes the potential of microRNAs (miRNAs) as biomarkers and therapeutic targets due to their crucial role in UC. This review explores the current understanding of miRNAs in UC, including their mechanisms of action and their potential as both biomarkers and therapeutic targets. The present review provides the latest update on their potential as a biomarker and therapeutic target.Areas covered: This review synthesizes an extensive literature search on miRNAs in UC, focusing on their roles in the mucosal barrier, innate and adaptive immunity, and their potential applications as biomarkers and therapeutic modalities.Expert opinion: While miRNAs present promising opportunities as biomarkers and novel therapeutic agents in UC, challenges in validation, specificity, delivery, and clinical application need to be addressed through rigorous, large-scale studies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"829-841"},"PeriodicalIF":4.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1080/14728222.2024.2408423","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The global rise in ulcerative colitis (UC) incidence highlights the urgent need for enhanced diagnostic and therapeutic strategies. Recent advances in genome-wide association studies (GWAS) have identified genetic loci associated with UC, providing insights into the disease's molecular mechanisms, including immune modulation, mucosal defense, and epithelial barrier function. Despite these findings, many GWAS signals are located in non-coding regions and are linked to low risk, suggesting that protein-coding genes alone do not fully explain UC's pathophysiology. Emerging research emphasizes the potential of microRNAs (miRNAs) as biomarkers and therapeutic targets due to their crucial role in UC. This review explores the current understanding of miRNAs in UC, including their mechanisms of action and their potential as both biomarkers and therapeutic targets. The present review provides the latest update on their potential as a biomarker and therapeutic target.

Areas covered: This review synthesizes an extensive literature search on miRNAs in UC, focusing on their roles in the mucosal barrier, innate and adaptive immunity, and their potential applications as biomarkers and therapeutic modalities.

Expert opinion: While miRNAs present promising opportunities as biomarkers and novel therapeutic agents in UC, challenges in validation, specificity, delivery, and clinical application need to be addressed through rigorous, large-scale studies.

查看原文本刊更多论文

溃疡性结肠炎中 MicroRNA 的靶标潜力：我们知道些什么？

导言：全球溃疡性结肠炎（UC）发病率的上升凸显了加强诊断和治疗策略的迫切需要。全基因组关联研究（GWAS）的最新进展确定了与溃疡性结肠炎相关的基因位点，为了解该疾病的分子机制（包括免疫调节、粘膜防御和上皮屏障功能）提供了线索。尽管有这些发现，但许多 GWAS 信号都位于非编码区，而且与低风险有关，这表明仅靠蛋白编码基因并不能完全解释 UC 的病理生理学。新近的研究强调了微小核糖核酸（miRNA）作为生物标志物和治疗靶点的潜力，因为它们在 UC 中起着至关重要的作用。本综述探讨了目前对 miRNA 在 UC 中作用的认识，包括其作用机制及其作为生物标记物和治疗靶点的潜力。本综述就 miRNA 作为生物标志物和治疗靶点的潜力提供了最新信息：本综述综合了有关 miRNAs 在 UC 中的广泛文献检索，重点关注 miRNAs 在粘膜屏障、先天性和适应性免疫中的作用，以及它们作为生物标志物和治疗方式的潜在应用：虽然miRNAs作为UC的生物标记物和新型治疗药物带来了大好机会，但在验证、特异性、传递和临床应用方面的挑战需要通过严格的大规模研究来解决。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.